Este documento discute vários temas relacionados à sabedoria, incluindo a sabedoria de Deus, o caminho da sabedoria, os pensamentos de Deus e de Cristo, e a necessidade de buscar primeiro o reino de Deus.
A Brief Overview of the Harvard College Fund Parents CommitteeBruce Furst
With a bachelor’s degree from the University of California, Los Angeles, and a juris doctor, Bruce Furst serves as president of Ashber Corporation, an entertainment licensing company based in Austin, Texas. Outside of work, Bruce Furst supports the Harvard College Fund Parents Committee.
The pharmaceutical industry in Europe is expected to grow at an annual rate of 3.2% from 2015-2022, driven by new innovations emerging across therapy areas like oncology and immunology. While oncology drugs will account for much of the growth, the top-selling drug in Europe in 2022 is predicted to be Xarelto rather than a cancer drug. Five of the top 10 drugs will treat cancer. However, funding all these new high-cost therapies may challenge healthcare systems. Pharmaceutical companies and payers will need to collaborate more closely on new funding models to support continued innovation.
Este documento discute vários temas relacionados à sabedoria, incluindo a sabedoria de Deus, o caminho da sabedoria, os pensamentos de Deus e de Cristo, e a necessidade de buscar primeiro o reino de Deus.
A Brief Overview of the Harvard College Fund Parents CommitteeBruce Furst
With a bachelor’s degree from the University of California, Los Angeles, and a juris doctor, Bruce Furst serves as president of Ashber Corporation, an entertainment licensing company based in Austin, Texas. Outside of work, Bruce Furst supports the Harvard College Fund Parents Committee.
The pharmaceutical industry in Europe is expected to grow at an annual rate of 3.2% from 2015-2022, driven by new innovations emerging across therapy areas like oncology and immunology. While oncology drugs will account for much of the growth, the top-selling drug in Europe in 2022 is predicted to be Xarelto rather than a cancer drug. Five of the top 10 drugs will treat cancer. However, funding all these new high-cost therapies may challenge healthcare systems. Pharmaceutical companies and payers will need to collaborate more closely on new funding models to support continued innovation.